» Articles » PMID: 29367550

The Physiopathology of Cardiorenal Syndrome: A Review of the Potential Contributions of Inflammation

Overview
Date 2018 Jan 26
PMID 29367550
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Inter-organ crosstalk plays an essential role in the physiological homeostasis of the heart and other organs, and requires a complex interaction between a host of cellular, molecular, and neural factors. Derangements in these interactions can initiate multi-organ dysfunction. This is the case, for instance, in the heart or kidneys where a pathological alteration in one organ can unfavorably affect function in another distant organ; attention is currently being paid to understanding the physiopathological consequences of kidney dysfunction on cardiac performance that lead to cardiorenal syndrome. Different cardiorenal connectors (renin-angiotensin or sympathetic nervous system activation, inflammation, uremia, etc.) and non-traditional risk factors potentially contribute to multi-organ failure. Of these, inflammation may be crucial as inflammatory cells contribute to over-production of eicosanoids and lipid second messengers that activate intracellular signaling pathways involved in pathogenesis. Indeed, inflammation biomarkers are often elevated in patients with cardiac or renal dysfunction. Epigenetics, a dynamic process that regulates gene expression and function, is also recognized as an important player in single-organ disease. Principal epigenetic modifications occur at the level of DNA (i.e., methylation) and histone proteins; aberrant DNA methylation is associated with pathogenesis of organ dysfunction through a number of mechanisms (inflammation, nitric oxide bioavailability, endothelin, etc.). Herein, we focus on the potential contribution of inflammation in pathogenesis of cardiorenal syndrome.

Citing Articles

Cardiorenal Disease and Heart Failure with Preserved Ejection Fraction: Two Sides of the Same Coin.

Nunez-Marina G, Nunez-Marin G, Santas E Cardiorenal Med. 2025; 15(1):108-121.

PMID: 39778558 PMC: 11844673. DOI: 10.1159/000543390.


Associations of C-reactive protein-albumin-lymphocyte (CALLY) index with cardiorenal syndrome: Insights from a population-based study.

Xu Z, Tang J, Chen X, Jin Y, Zhang H, Liang R Heliyon. 2024; 10(17):e37197.

PMID: 39296012 PMC: 11408039. DOI: 10.1016/j.heliyon.2024.e37197.


Identification of Shared Signature Genes and Immune Microenvironment Subtypes for Heart Failure and Chronic Kidney Disease Based on Machine Learning.

Wang X, Rao J, Chen X, Wang Z, Zhang Y J Inflamm Res. 2024; 17:1873-1895.

PMID: 38533476 PMC: 10964169. DOI: 10.2147/JIR.S450736.


Traditional herbal medicine use doubled the risk of multi-organ dysfunction syndrome in children: A prospective cohort study.

Teshager N, Amare A, Tamirat K, Zeleke M, Taddese A PLoS One. 2024; 19(2):e0286233.

PMID: 38394174 PMC: 10889611. DOI: 10.1371/journal.pone.0286233.


Evaluation of progression of chronic kidney disease in dogs with myxomatous mitral valve disease.

Yun H, Koo Y, Yun T, Chae Y, Lee D, Cha S Front Vet Sci. 2023; 10:1200653.

PMID: 37691634 PMC: 10484475. DOI: 10.3389/fvets.2023.1200653.


References
1.
Ford D, Hale C . Plasmalogen and anionic phospholipid dependence of the cardiac sarcolemmal sodium-calcium exchanger. FEBS Lett. 1996; 394(1):99-102. DOI: 10.1016/0014-5793(96)00930-1. View

2.
Chen X, Gross R . Phospholipid subclass-specific alterations in the kinetics of ion transport across biologic membranes. Biochemistry. 1994; 33(46):13769-74. DOI: 10.1021/bi00250a030. View

3.
Delvaeye M, Conway E . Coagulation and innate immune responses: can we view them separately?. Blood. 2009; 114(12):2367-74. DOI: 10.1182/blood-2009-05-199208. View

4.
Heidt T, Sager H, Courties G, Dutta P, Iwamoto Y, Zaltsman A . Chronic variable stress activates hematopoietic stem cells. Nat Med. 2014; 20(7):754-758. PMC: 4087061. DOI: 10.1038/nm.3589. View

5.
El-Sherbeni A, El-Kadi A . Alterations in cytochrome P450-derived arachidonic acid metabolism during pressure overload-induced cardiac hypertrophy. Biochem Pharmacol. 2013; 87(3):456-66. DOI: 10.1016/j.bcp.2013.11.015. View